reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Reviva Pharmaceuticals Holdings, Inc.

RVPH · OTC

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$21Mpublic float
2025-06-06most recent failure
2024-04-15declared past accounts unreliable

Score over time

01234202220232024202520262022-01-01 · score 12021-05-07 accounts unreliable2022-04-01 · score 12021-05-07 accounts unreliable2023-10-01 · score 12023-07-24 auditor change2024-01-01 · score 22023-10-04 auditor change2023-07-24 auditor change2024-04-01 · score 22023-10-04 auditor change2023-07-24 auditor change2024-07-01 · score 42024-04-15 accounts unreliable2024-04-02 filed late (10-K) · material weakness2023-10-04 auditor change2023-07-24 auditor change2024-10-01 · score 32024-04-15 accounts unreliable2024-04-02 filed late (10-K) · material weakness2023-10-04 auditor change2025-01-01 · score 22024-04-15 accounts unreliable2024-04-02 filed late (10-K) · material weakness2025-04-01 · score 32025-03-31 filed late (10-K) · material weakness2024-04-15 accounts unreliable2024-04-02 filed late (10-K) · material weakness2025-07-01 · score 22025-06-06 auditor change2025-03-31 filed late (10-K) · material weakness2025-10-01 · score 22025-06-06 auditor change2025-03-31 filed late (10-K) · material weakness2026-01-01 · score 22025-06-06 auditor change2025-03-31 filed late (10-K) · material weakness2026-04-01 · score 12025-06-06 auditor change

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), is unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) by the prescribed due date without unreasonable effort or expense because of the circumstances described below. The Company is working diligently to complete and finalize the 2024 Form 10-K, including the Company’s financial statements to be included therein and related audit procedures necessary for the issuance of such financial statements, so that the 2024 Form 10-K can be filed as soon as possible. However, additional time is required for the Company to complete and finalize the 2024 Form 10-K and the Company’s financial statements. Although the assessment is not yet complete, the Company expects to report material weaknesses in its internal control over financial reporting and its disclosure controls and procedures. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 will be filed on or before the fifteenth calendar day following the prescribed due date

NT 10-K, filed 2025-03-31 · material weakness

What it filed

2025-06-06auditor changed or resigned SEC →

2025-03-31filed late (10-K)material weakness SEC →

Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), is unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) by the prescribed due date without unreasonable effort or expense because of the circumstances described below. The Company is working diligently to complete and finalize the 2024 Form 10-K, including the Company’s financial statements to be included therein and related audit procedures necessary for the issuance of such financial statements, so that the 2024 Form 10-K can be filed as soon as possible. However, additional time is required for the Company to complete and finalize the 2024 Form 10-K and the Company’s financial statements. Although the assessment is not yet complete, the Company expects to report material weaknesses in its internal control over financial reporting and its disclosure controls and procedures. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 will be filed on or before the fifteenth calendar day following the prescribed due date

2024-04-15accounts declared unreliable SEC →

2024-04-02filed late (10-K)material weakness SEC →

Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”) is unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”) by the prescribed due date without unreasonable effort or expense because of the circumstances described below. The Company is working diligently to complete and finalize the 2023 Form 10-K, including the Company’s financial statements to be included therein, so that the 2023 Form 10-K can be filed as soon as possible. However, additional time is required for the Company to complete and finalize the 2023 Form 10-K and the Company’s financial statements, and to obtain an audit report on the Company's financial statements, including for the Company to finalize its review in connection with certain of the Company’s clinical trials and the impact of such expenses on the Company’s financial statements. Although the assessment is not yet complete, the Company expects to report a related material weakness in its internal controls over financial reporting and its disclosure controls and procedures. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 will be filed on or before the fifteenth calendar day following the prescribed due date

2023-10-04auditor changed or resigned SEC →

2023-07-24auditor changed or resigned SEC →

2021-05-07accounts declared unreliable SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com